Starling Oncology Q3 operating loss narrows 63% year over year to $2.98 million

PUBT · 1d ago
Starling Oncology Q3 operating loss narrows 63% year over year to $2.98 million
  • Starling Oncology’s third-quarter 2026 net loss narrowed year over year to $15.75 million.
  • Revenue climbed 24% year over year to $169.77 million.
  • Specialty Pharmacy revenue rose 44% year over year to $109.3 million, primarily due to increased capture of prescriptions written by Starling physicians.
  • The Starling Nexus utilization management portal is now live for network providers across all markets with delegated capitation arrangements.
  • FY26 revenue guidance narrowed to $650 million–$660 million from $650 million–$670 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Starling Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051606PRIMZONEFULLFEED9871757) on November 05, 2026, and is solely responsible for the information contained therein.